Envisioneering Medical Technologies, a St. Louis, MO firm, recently released its advanced ultrasound imaging and brachytherapy placement device for treatment of prostate cancer.
From the press release:
Just launched, the system will initially be in clinical use at Emory, Washington University Medical Center in St. Louis, University of Florida and New Hanover Radiation Oncology.
The system is based on the TargetScan® technology platform developed by Envisioneering Medical Technologies in St. Louis, under the guidance of physicians at Washington University. “Traditional hand-manipulated devices allow the prostate gland to shift, which impedes placement accuracy. By stabilizing the prostate, physicians can now implant seeds to any and every region of the gland with greater confidence,” said Robert Mills, president, Envisioneering Medical Technologies.
TargetScan Touch Technical Features:
Motionless probe to prevent prostate movement and on-screen image distortion. Mapping technology for complete prostatic coverage, assisting with accurate needle placement to pre-planned cancer targets and preferred treatment zones 3-D image acquisition to improve visibility, presenting both sagittal and transverse planes with a total viewing volume of 380 mL. Touch-screen technology to improve treatment efficiency and patient experience.
Here’s a company video introducing the TargetScan…
Press release: Technology Designed to Confirm Precise Brachytherapy Treatment…
Product page: TargetScan Touch 3D Ultrasound System
Device brochure (.pdf)…